Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.39%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.31%AUDSGD+0.31%GBPUSD+0.30%NZDSGD+0.30%GBPMXN-0.28%USDTRY+0.27%NZDUSD+0.27%CHFJPY-0.27%AUDUSD+0.26%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%GBPJPY+0.22%USDZAR-0.21%USDCHF+0.20%GBPSGD+0.20%EURAUD-0.18%AUDJPY+0.18%NZDJPY+0.18%NOKJPY+0.17%EURNZD-0.17%EURNOK-0.16%USDILS+0.16%AUDDKK+0.16%CHFNOK-0.16%CHFSGD+0.16%NZDCAD-0.16%USDSEK-0.16%EURSGD+0.15%USDPLN-0.15%SGDJPY-0.14%AUDCAD-0.13%EURZAR-0.12%EURHKD+0.09%USDDKK-0.09%GBPZAR-0.08%GBPCAD-0.08%USDJPY-0.07%PLNJPY+0.07%EURSEK-0.07%EURCNH+0.06%CHFSEK-0.06%EURUSD+0.06%USDSGD+0.06%GBPAUD+0.06%EURPLN-0.06%USDCOP-0.04%GBPNZD+0.03%USDCNH-0.03%USDTHB+0.03%AUDNZD+0.02%USDMXN-0.01%EURJPY-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%HG1+0.74%COTTON+0.71%S1+0.47%XNGUSD+0.32%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.18%USOIL-0.16%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.06%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.57%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.27%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.37%HBARUSDT+0.35%TONUSD+26.15%TAOUSDT+3.90%AAVEUSD+3.58%DOTUSDT-0.20%ICPUSDT+0.78%ONDOUSDT+0.36%WLDUSDT-0.02%ARBUSDT+6.66%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.30%STXUSDT+6.52%FETUSDT+2.74%TIAUSDT+9.19%PYTHUSDT-0.74%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.88%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.70%DYDXUSDT+3.44%GALAUSDT-1.87%ORDIUSDT-0.09%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.39%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.31%AUDSGD+0.31%GBPUSD+0.30%NZDSGD+0.30%GBPMXN-0.28%USDTRY+0.27%NZDUSD+0.27%CHFJPY-0.27%AUDUSD+0.26%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%GBPJPY+0.22%USDZAR-0.21%USDCHF+0.20%GBPSGD+0.20%EURAUD-0.18%AUDJPY+0.18%NZDJPY+0.18%NOKJPY+0.17%EURNZD-0.17%EURNOK-0.16%USDILS+0.16%AUDDKK+0.16%CHFNOK-0.16%CHFSGD+0.16%NZDCAD-0.16%USDSEK-0.16%EURSGD+0.15%USDPLN-0.15%SGDJPY-0.14%AUDCAD-0.13%EURZAR-0.12%EURHKD+0.09%USDDKK-0.09%GBPZAR-0.08%GBPCAD-0.08%USDJPY-0.07%PLNJPY+0.07%EURSEK-0.07%EURCNH+0.06%CHFSEK-0.06%EURUSD+0.06%USDSGD+0.06%GBPAUD+0.06%EURPLN-0.06%USDCOP-0.04%GBPNZD+0.03%USDCNH-0.03%USDTHB+0.03%AUDNZD+0.02%USDMXN-0.01%EURJPY-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%HG1+0.74%COTTON+0.71%S1+0.47%XNGUSD+0.32%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.18%USOIL-0.16%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.06%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.57%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.27%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.37%HBARUSDT+0.35%TONUSD+26.15%TAOUSDT+3.90%AAVEUSD+3.58%DOTUSDT-0.20%ICPUSDT+0.78%ONDOUSDT+0.36%WLDUSDT-0.02%ARBUSDT+6.66%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.30%STXUSDT+6.52%FETUSDT+2.74%TIAUSDT+9.19%PYTHUSDT-0.74%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.88%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.70%DYDXUSDT+3.44%GALAUSDT-1.87%ORDIUSDT-0.09%RONINUSDT-3.42%NOTUSDT+1.21%
AB

Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ • Healthcare

$26.09
-$0.12 (-0.5%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$26.17
Day Range$25.6 - $26.57
Avg. Volume (3M)3.3M
Market Cap$3.2B
P/E Ratio118.6
52 Week Range
$19.3$31.77
Next EarningsIn 13 daysOct 27, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$129.8M100%
Gross Profitminus cost of goods$118.9M92%
Operating Incomeminus R&D and overhead$16.4M13%
Net Incomeminus taxes and the rest$15M12%

In plain terms: out of every $100 in revenue, Arcutis Biotherapeutics, Inc. keeps $12 as net profit.

Fundamentals & Financials

Revenue (TTM)
$463.9M
Net Income (TTM)
$28.5M
EPS (TTM)
$0.22
ROA (TTM)
5.84%
Current Ratio
2.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+333.3%Q1 2026$0.13
-350.0%Q2 2026-$0.09
+99.7%Q3 2026$0.11
Next

Oct 27

in 13 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Arcutis Biotherapeutics, Inc. (ARQT) is set to report on October 27, 2026. Wall Street is looking for consensus EPS of $0.17 on consensus revenue of $141.7 million. For trailing context, revenue grew +59.3% year over year last quarter. ARQT has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. develops and markets therapies for skin-related diseases and operates as a biotechnology company listed on the NASDAQ under ARQT. In FY2025, the company generated $376.1 million in revenue. Formerly known as Arcutis, Inc., it focuses on dermatology products and pipeline programs built around inflammatory skin conditions.

Name
Arcutis Biotherapeutics, Inc.
CEO
Todd Franklin Watanabe
Website
www.arcutis.com
Industry
Healthcare
Year Founded
2016
Employees
354

Today's Snapshot

AI-generated

The day ended with ARQT 0.5% lower at 26.09, in line with a weaker sector. Arcutis CEO Frank Watanabe tied Zoryve, a steroid-free skin treatment, to a $525 million sales forecast. ARQT is due to report earnings on 27 October.

Trading Volume

Below 10d avg (2.0M)

1.8M

vs S&P 500 Today

Moderate Underperformance

-0.48%

Updated: October 13, 2026 at 20:11 UTC

ARQT Headlines

FDA clears ZORYVE cream for children 2+

June 30, 2026

3 min read
View All News

Technical Indicators

6 Buy2 Neutral0 Sell
ARQT’s readings support a strong-buy bias as price sits above its short-, medium- and long-term averages and momentum shows modest constructive evidence. Momentum indicators are mixed-to-favorable with RSI slightly above midline and a small positive MACD, while trend strength is relatively weak (ADX about 18) so the advance lacks strong trend confirmation. Volatility is moderate with ATR near 1.24 and, notably, on-balance volume is negative which tempers conviction. The classic pivot is close to the current price, indicating near-term balance. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$25.33 - $25.63
    Buy
  • RSI (14)53.29
    Neutral
  • Stochastic %K (14, 3, 3)63.41
    Neutral
  • MACD Level (12, 26)0.07
    Buy

Peers & Related Assets

ALDXAldeyra The
$0.9-0.7%
ACRSAclaris Therapeutics, Inc.
TTRXTurn Therapeutics Inc.
SLGLSol-Gel Technologies Ltd.
EVMNEvommune, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.